Kronos Advanced Technologies, Inc. (OTC: KNOS) Announces Ex-Dividend Date for Upcoming Special Cash Dividend
September 16, 2024 03:18 ET
|
Kronos Advanced Technologies Inc.
Los Angeles, CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Los Angeles, CA September 16, 2024– Kronos Advanced Technologies, Inc. (OTC: KNOS), a leading innovator in advanced air purification technology,...
SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) and Updates its Expected FDA Approval Timeline
September 11, 2024 08:30 ET
|
SS Innovations
SS Innovations Conducts Interactive Meeting with the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA)
NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study
September 06, 2024 16:03 ET
|
NurExone Biologic Inc
NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
Politicized Medicine Hindered Use of Ivermectin for COVID, according to the Journal of American Physicians and Surgeons
September 04, 2024 11:12 ET
|
Association of American Physicians and Surgeons
The politicized response to Covid included a war on the use of ivermectin. Studies have conflicting results. The issue is at a stalemate.
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
September 03, 2024 09:00 ET
|
Longeveron
Longeveron announces positive Type C meeting with FDA, clarifying regulatory pathway to BLA submission for Lomecel-B for hypoplastic left heart syndrome.
Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML
September 03, 2024 08:00 ET
|
Caribou Biosciences, Inc.
-- Fast Track designation is designed to expedite clinical development and regulatory review timelines -- -- Additional FDA designation for CB-010 following earlier RMAT and Fast Track...
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
August 29, 2024 14:14 ET
|
Spherix Global Insights
EXTON, PA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- The past few months have ushered in a new era of treatment for patients suffering from primary biliary cholangitis (PBC), marked by the approval of...
Kronos Advanced Technologies Announces Letter of Intent to Acquire Leading Data-Marketing and Direct to Consumer marketing Company, Suarez Corporation Industries, for Total Potential Consideration of $25 Million
August 27, 2024 06:18 ET
|
Kronos Advanced Technologies Inc.
PArkersburg, West Virginia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Parkersburg, WV - August 27, 2024 - Kronos Advanced Technologies Inc. (OTC: KNOS), a leader in advanced air purification and innovative...
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
August 22, 2024 14:15 ET
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and olderThe KP.2 adaptation is based on FDA...
Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD
August 22, 2024 06:00 ET
|
Liquidia Corporation
Liquidia has filed litigation that challenges the recent decision by the FDA to grant 3-year new clinical investigation exclusivity to Tyvaso DPI.